Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
telomerase inhibitor |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2024
|
| gptkbp:approvedBy |
gptkb:United_States
gptkb:FDA |
| gptkbp:ATCCode |
L01XX81
|
| gptkbp:CASNumber |
1042060-23-3
|
| gptkbp:chemicalFormula |
C252H366N76O68P16
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
Geron Corporation
|
| https://www.w3.org/2000/01/rdf-schema#label |
Imetelstat
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits telomerase activity
|
| gptkbp:molecularWeight |
6792.6 g/mol
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
neutropenia
thrombocytopenia liver function abnormalities |
| gptkbp:synonym |
gptkb:GRN163L
|
| gptkbp:target |
telomerase reverse transcriptase (hTERT)
|
| gptkbp:UNII |
6Z5F4XW6F2
|
| gptkbp:usedFor |
gptkb:myelofibrosis
myelodysplastic syndromes |
| gptkbp:bfsParent |
gptkb:Telomerase
|
| gptkbp:bfsLayer |
7
|